21-46116045-G-C
Variant summary
Our verdict is Pathogenic. Variant got 14 ACMG points: 14P and 0B. PS1PM2PM5PP3_StrongPP5_Moderate
The NM_001849.4(COL6A2):c.892G>C(p.Gly298Arg) variant causes a missense change. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★). Another nucleotide change resulting in same amino acid change has been previously reported as Pathogenicin Lovd. Another variant affecting the same amino acid position, but resulting in a different missense (i.e. G298V) has been classified as Likely pathogenic.
Frequency
Consequence
NM_001849.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 14 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
COL6A2 | NM_001849.4 | c.892G>C | p.Gly298Arg | missense_variant | 7/28 | ENST00000300527.9 | NP_001840.3 | |
COL6A2 | NM_058174.3 | c.892G>C | p.Gly298Arg | missense_variant | 7/28 | NP_478054.2 | ||
COL6A2 | NM_058175.3 | c.892G>C | p.Gly298Arg | missense_variant | 7/28 | NP_478055.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
COL6A2 | ENST00000300527.9 | c.892G>C | p.Gly298Arg | missense_variant | 7/28 | 1 | NM_001849.4 | ENSP00000300527.4 | ||
COL6A2 | ENST00000397763.6 | c.892G>C | p.Gly298Arg | missense_variant | 7/28 | 5 | ENSP00000380870.1 | |||
COL6A2 | ENST00000409416.6 | c.892G>C | p.Gly298Arg | missense_variant | 6/27 | 5 | ENSP00000387115.1 | |||
COL6A2 | ENST00000485591.1 | n.548G>C | non_coding_transcript_exon_variant | 3/7 | 3 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 33
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Bethlem myopathy 1A Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 06, 2022 | This sequence change replaces glycine, which is neutral and non-polar, with arginine, which is basic and polar, at codon 298 of the COL6A2 protein (p.Gly298Arg). For these reasons, this variant has been classified as Pathogenic. This variant disrupts the triple helix domain of COL6A2. Glycine residues within the Gly-Xaa-Yaa repeats of the triple helix domain are required for the structure and stability of fibrillar collagens (PMID: 7695699, 8218237, 19344236). In COL6A2, missense variants at these glycine residues are significantly enriched in individuals with autosomal dominant disease (PMID: 15689448, 24038877) compared to the general population (ExAC). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt COL6A2 protein function. ClinVar contains an entry for this variant (Variation ID: 855625). This missense change has been observed in individuals with clinical features of type VI collagenopathy (PMID: 18825676; Invitae). This variant is not present in population databases (gnomAD no frequency). - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at